In a murine bladder model (MB49), Goswami et al. also showed that the combination therapy of EZH2 inhibition (via CPI-1205) and anti-CTLA-4 were capable of mediating a more significant tumor growth inhibition than the respective monotherapies (48). This evidence concerns the gene EZH2 and neoplasm.